γδ T Cells in Tumor Microenvironment

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Gamma delta (γδ) T cells possess both innate and adaptive immune capabilities, exhibiting significant cytotoxic and pro-inflammatory functions against various tumor cells.
• These cells are frequently found within tumors (tumor-infiltrating lymphocytes) and can serve as prognostic markers, although their role varies by cancer type, sometimes correlating with poor prognosis in breast and colon cancers.
• The tumor microenvironment critically influences γδ T-cell behavior, potentially directing them towards tumor-promoting or tumor-controlling phenotypes, thus impacting their therapeutic effectiveness.

Purpose of the Study:

• To review the fundamental characteristics of γδ T cells and their involvement in the tumor microenvironment.
• To analyze recent advancements in understanding γδ T-cell activation within tumors and the associated therapeutic challenges.
• To discuss current and future perspectives for γδ T-cell-based cancer immunotherapies.

Main Methods:

• Review of existing scientific literature on γδ T cells, tumor microenvironment interactions, and immunotherapeutic strategies.
• Analysis of the activation mechanisms of Vγ9Vδ2 T cells, including their reliance on butyrophilin 3A (BTN3A) expression.
• Examination of ex vivo and in vivo therapeutic approaches utilizing γδ T cells.

Main Results:

• γδ T cells are crucial in anti-tumor immunity, with Vγ9Vδ2 T cells being a major subset activated by phosphoantigens via BTN3A.
• The tumor microenvironment can modulate BTN3A expression and γδ T-cell function, presenting challenges for immunotherapy.
• Current therapeutic strategies involving Vγ9Vδ2 T cells, such as adoptive transfer and in vivo expansion, show promise but require optimization.

Conclusions:

• γδ T cells, particularly Vγ9Vδ2 T cells, hold significant therapeutic potential against cancer due to their potent anti-tumor properties.
• Overcoming the immunosuppressive effects of the tumor microenvironment and optimizing T-cell activation are key challenges for effective γδ T-cell immunotherapy.
• Combining γδ T-cell-based therapies with systemic treatments to modulate the tumor microenvironment may enhance overall anti-tumor immune responses and improve patient outcomes.